TORONTO, Aug. 28,
2023 /CNW/ - Grey Wolf Animal Health Corp. (TSXV:
WOLF) ("Grey Wolf" or the "Company"), a Canadian diversified animal
health company, today announced financial results for the quarter
and six months ended June 30,
2023.
Highlights
- Revenue for the quarter increased year over year by 8.8% to
$6.7 million. Revenue increased by
12.6% to $12.7 million for the first
six months of the year.
- Gross profit increased year over year by 5.5% to $3.4 million for the quarter and 12.9% to
$6.5 million for the first six months
of the year.
- Adjusted EBITDA1 was $1.1
million for the quarter compared to $1.1 million for the same period in 2022.
Adjusted EBITDA1 for the first six months of the year
was $2.0 million compared to
$2.0 million in the prior year.
"The second quarter of 2022 was a continuation of what we
experienced in the first quarter. We saw revenue grow by 8.8% to
$6.7 million driven by organic growth
within our product portfolio as well as new products launched in
2022. Gross margins have remained consistent with previous quarters
due to the product mix sold in our Animal Health and Pharmacy
businesses during the first six months of 2023. In addition, even
as we absorb the additional costs associated with operating a
public entity our Adjusted EBITDA1 has remained
steady." said Angela Cechetto, Chief
Executive Officer.
Key Financial Data and Comparative Results
|
Three months ended
|
Six months ended
|
|
Jun 30, 2023
|
Jun 30, 2022
|
Jun 30, 2023
|
Jun 30, 2022
|
|
|
|
|
|
Revenue
|
6,681,181
|
6,140,758
|
12,725,777
|
11,298,053
|
Gross profit
|
3,371,233
|
3,194,003
|
6,547,015
|
5,800,164
|
Gross profit
%
|
50.5 %
|
52.0 %
|
51.4 %
|
51.3 %
|
Total operating
expenses
|
2,721,740
|
3,428,525
|
5,378,128
|
5,997,858
|
Operating income (loss)
for the period
|
649,493
|
(234,522)
|
1,168,887
|
(197,694)
|
|
|
|
|
|
Income tax expense
(recovery)
|
328,730
|
(128,004)
|
298,837
|
(167,619)
|
Net income (loss) for
the period
|
200,492
|
(1,099,802)
|
610,955
|
(2,109,574)
|
|
|
|
|
|
Earnings (loss) per
share
|
|
|
|
|
Basic and
diluted
|
0.01
|
(0.08)
|
0.02
|
(0.14)
|
|
|
|
|
|
EBITDA
|
1,014,120
|
(48,674)
|
1,879,089
|
160,517
|
Adjusted
EBITDA
|
1,069,575
|
1,127,952
|
2,007,891
|
1,974,000
|
|
|
|
|
|
|
|
|
Jun 30, 2023
|
Dec 31, 2022
|
|
|
|
|
|
Total assets
|
|
|
38,826,504
|
39,309,105
|
Total liabilities
|
|
|
13,851,869
|
15,061,717
|
Results of Operations for the
Three and Six Months ended June 30,
2023
Revenue for the three- and six-month period ended June 30, 2023, increased 8.8% to $6.7 million and 12.6% to $12.7 million, respectively, over the same
periods in 2022. These increases were due to organic revenue growth
from the Animal Health and Pharmacy business units.
Gross margins for the three- and six-month period ended
June 30, 2023, decreased to 50.5%
compared to 52.0% and remained consistent at 51.4% and 51.3%,
respectively, over the same period in 2022. Gross margins were
impacted by the product mix in both the Animal Health and Pharmacy
business units.
Total expenses for the three- and six-month period ended
June 30, 2023, decreased 20.6% to
$2.7 million and 10.3% to
$5.4 million, respectively, over the
same period in 2022. The decrease in total expenses was largely
related to costs associated with the Qualifying Transaction during
the same periods in 2022 offset by costs noted below. During the
three-month period, there was an increase in salary, bonus, and
benefits related to operational growth as compared to the same
period in 2022. Travel, meals, and business expenses increased in
2023 as the sales and marketing team increased attendance at
conventions, trade shows and customer visits. Finally, there was an
increase in professional fees and outside services related to
corporate costs as the company now operates as a public entity.
Adjusted EBITDA1 was $1.1
million and $2.0 million for
the three- and six-month period ended June
30, 2023 consistent with the same periods in 2022 as the
Company absorbed costs associated with operating as a public entity
in 2023.
Cash and cash equivalents were $6.7
million as at June 30, 2023
compared to $6.9 million at
December 31, 2022. The Company
generated cash from operations of $0.5
million in the first half of 2023 million primarily as a
result of net income for the current period offset by changes in
trade and other receivables, inventories and accounts payable and
accrued liabilities. As at June 30,
2023, the Company had outstanding borrowings of $9.7 million, of which $1.1 million are current and $8.6 million are non-current. The Company's debt
is a fixed rate term loan with an average interest rate of 4.7%
until September 2026. In addition, the Company repaid
borrowings of $0.5 million since
December 31, 2022.
Grey Wolf's financial statements and accompanying Management
Discussion and Analysis for the three- and six-months ended
June 30, 2023 are available under the
Company's profile on www.sedar.com.
1Non-IFRS
Measures
Management uses both IFRS and Non-IFRS Measures to assess the
financial and operating performance of the Company's operations.
These Non-IFRS Measures are not recognized measures under IFRS, do
not have a standardized meaning under IFRS and are unlikely to be
comparable to similar measures presented by other companies. The
Non-IFRS Measures referenced in this press release includes
Adjusted EBITDA. The Company defines Adjusted EBITDA as earnings
before financing and special transaction costs (including, for
greater certainty, fees related to the Qualifying Transaction),
interest income, interest and accretion expenses, income taxes,
depreciation of property and equipment, depreciation of right of
use assets, amortization of intangible assets, share-based
compensation, change in fair value of embedded derivatives, foreign
exchange gains or losses, and other income. The Company considers
Adjusted EBITDA as an additional metric in assessing business
performance and an important measure of operating performance and
cash flow, providing useful information to help analyze and compare
profitability between companies for investors and analysts.
The following table provides a summary of the differences
between Grey Wolf's consolidated IFRS and Non-IFRS financial
measures, which are reconciled below:
EBITDA and Adjusted EBITDA
|
Three months ended
|
Six months ended
|
|
Jun 30, 2023
|
Jun 30, 2022
|
Jun 30, 2023
|
Jun 30, 2022
|
|
|
|
|
|
Net income (loss) for the
period
|
200,492
|
(1,099,802)
|
610,955
|
(2,109,574)
|
|
|
|
|
|
Interest
income
|
(28,725)
|
-
|
(60,473)
|
-
|
Interest and accretion
expense
|
151,687
|
820,516
|
307,058
|
1,612,522
|
Income taxes
|
328,730
|
(128,004)
|
298,837
|
(167,619)
|
Depreciation of
property and equipment
|
69,283
|
70,025
|
137,405
|
139,673
|
Depreciation of right
of use assets
|
48,903
|
44,841
|
97,807
|
89,682
|
Amortization of
intangible assets
|
243,750
|
243,750
|
487,500
|
595,833
|
|
|
|
|
|
EBITDA
|
1,014,120
|
(48,674)
|
1,879,089
|
160,517
|
|
|
|
|
|
Adjustments
|
|
|
|
|
Share-based
compensation
|
58,146
|
47,711
|
116,292
|
95,422
|
Change in fair value of
embedded derivatives
|
-
|
154,956
|
-
|
472,700
|
Foreign exchange loss
(gain)
|
(2,691)
|
17,812
|
12,510
|
4,277
|
Other income
|
-
|
-
|
-
|
(10,000)
|
Financing and special
transaction costs
|
-
|
956,147
|
-
|
1,251,084
|
|
|
|
|
|
Adjusted EBITDA
|
1,069,575
|
1,127,952
|
2,007,891
|
1,974,000
|
About Grey Wolf Animal Health
Corp.
Grey Wolf Animal Health Corp., headquartered in Toronto, Canada, is a diversified animal
health company founded by a veterinarian to bring to market a
broad portfolio of products that meets the unmet needs of
veterinarians, clinics and pets. The Company's strategy is to
in-license, acquire or develop innovative prescription and
non-prescription products for commercialization in the veterinarian
channel in Canada. For additional
information, please visit: www.greywolfah.com.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this news release.
Forward Looking
Statements
Certain information included in this press release contains
forward-looking information with the meaning of applicable Canadian
securities laws. This information includes statements concerning
the Company's objectives, its strategies to achieve those
objectives, as well as statements with respect to management's
beliefs, plans, estimates, and intentions, and similar statements
concerning anticipated future events, results, circumstances,
performance or expectations that are not historical facts.
Forward-looking information generally can be identified by the use
of forward-looking terminology such as "outlook", "objective",
"may", "will", "would", "expect", "intend", "estimate",
"anticipate", "believe", "should", "plan", "continue", or similar
expressions suggesting future outcomes or events or the negative
thereof. Such forward-looking information reflects management's
beliefs and is based on information currently available. All
forward-looking information in this press release is qualified by
the following cautionary statements.
Forward-looking information necessarily involve known and
unknown risks and uncertainties, which may be general or specific
and which give rise to the possibility that expectations,
forecasts, predictions, projections or conclusions will not prove
to be accurate, assumptions may not be correct and objectives,
strategic goals and priorities may not be achieved. A variety of
factors, many of which are beyond the Company's control, affect the
operations, performance and results of the Company and its
subsidiaries, and cause actual results to differ materially from
current expectations of estimated or anticipated events or
results.
A more detailed assessment of the risks that could cause
actual results to materially differ than current expectations is
contained in the Risk Factors section of Grey Wolf's Management
Discussion and Analysis for the three and six months ended
June 30, 2023. The forward-looking
information included in this press release is made as of the date
hereof and should not be relied upon as representing the Company's
views as of any date subsequent to the date hereof. Management
undertakes no obligation, except as required by applicable law, to
publicly update or revise any forward-looking information, whether
as a result of new information, future events or otherwise.
SOURCE Grey Wolf Animal Health Corp.